-- Gilead Sciences (GILD) reported Q1 adjusted earnings late Thursday of $2.03 per diluted share, up from $1.81 a year earlier.
Analysts polled by FactSet expected $1.91.
Revenue for the three months ended March 31 was $6.96 billion, up from $6.68 billion a year earlier.
Analysts surveyed by FactSet expected $6.91 billion.
For full-year 2026, Gilead now expects non-GAAP diluted loss of $0.65 to $1.05 per share, compared with the prior forecast for non-GAAP EPS of $8.45 to $8.85. Analysts expect EPS of $8.55.
The company kept its quarterly dividend at $0.82 per share, payable June 29 to stockholders of record June 15.